Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.

Clinical lung cancer - 1 Mar 2024

Inno Alessandro, Picece Vincenzo, Bogina Giuseppe, Settanni Giulio, Viassolo Valeria, Salgarello Matteo, Gori Stefania

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Indazoles
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Source

Identifiers

PMID: 38008640
DOI: 10.1016/j.cllc.2023.10.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.PMID 38008640Read ↗

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature ReviewSemantic proximity Read ↗

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read ↗

Exceptional Response to Olaparib: A Case Report of Metastatic Esophageal Squamous Cell Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 Mutations.Semantic proximity Read ↗

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity Read ↗

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.Semantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

FDA approves olaparib for germline BRCA-mutated metastatic breast cancerSemantic proximity Read ↗

Olaparib for Metastatic Germline BRCA-Mutated Breast CancerSemantic proximity Read ↗

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationSemantic proximity Read ↗

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.Semantic proximity Read ↗

Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report.Semantic proximity Read ↗

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.